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Purpose: Previously we showed that epithelial cell adhesion molecule (Ep-CAM), a cell surface molecule, was highly
expressed in primary retinoblastoma tumors. In the present study, we studied the genes regulated by Ep-CAM in a
retinoblastoma Y79 cell line in vitro using a combination of short interference RNA and microarray technology.
Methods:  Flow  cytometry,  quantitative  reverse  transcriptase  PCR  (Q-RT–PCR),  and  immunohistochemistry  were
performed to confirm the Ep-CAM re-expression in the Y79 cells treated with 5′-azacytidine (AZC). Ep-CAM expression
in AZC-treated Y79 cells was silenced using synthetic anti-Ep-CAM short interference RNA, and whole genome
microarray was performed to determine the gene expression changes post Ep-CAM knockdown. Ep-CAM inhibition was
confirmed by Q-RT–PCR, western blotting, and immunofluorescence.
Results: Ep-CAM expression was significantly restored in Y79 cells on day 5 of AZC treatment. Ep-CAM inhibition
significantly affected Y79 cell proliferation. We identified 465 upregulated genes (≥1.0 fold) and 205 downregulated
genes (≤0.5 fold) in response to knockdown of Ep-CAM. These genes regulate several aspects of tumor function, including
cell survival/proliferation, DNA replication/transcription, apoptosis, and angiogenesis. Quantitative pathway analysis
using Biointerpreter further revealed that the most pronounced effect of Ep-CAM knockdown was deregulation of
pathways that include mitogen-activated protein kinase (MAP) kinase and tumor protein 53 (P53) pathways. Real-time
Q-RT–PCR confirmed microarray gene expression changes for selected genes.
Conclusions: Ep-CAM silencing significantly decreases Y79 cell proliferation and revealed a wide network of deregulated
pathways in vitro. Future studies targeting Ep-CAM gene expression in vivo will help to delineate the mechanisms
associated with Ep-CAM gene function in neoplastic transformation and define the potential for Ep-CAM-based molecular
intervention in retinoblastoma patients.
Retinoblastoma (RB) is the most common intraocular
malignancy in children [1]. For many years retinoblastoma
confined to the eye has been a curable disease with local
therapy,  such  as  enucleation,  external  beam  irradiation,
brachytherapy,  cryotherapy,  or  laser  coagulation  [2].  In
contrast,  systemic  disease  is  difficult  to  cure,  although  it
usually responds to chemotherapy [3–5]. The advent of short
interfering (si)RNA might prove a useful addition to, or a
substitute for, conventional treatment modalities. Previously
we demonstrated the expression of epithelial cell adhesion
molecule (Ep-CAM) in RB tumor tissues, and the tumors with
choroidal invasion/optic nerve invasion showed significantly
higher expression of Ep-CAM [6]. Ep-CAM is a 40,000 MW
type  I  transmembrane  glycoprotein  that  consists  of  two
epidermal  growth  factor-like  extracellular  domains,  a
cysteine-poor region, a transmembrane domain, and a short
cytoplasmic  tail.  Ep-CAM  is  overexpressed  in  various
epithelial cancers [7] and is an ideal therapeutic target because
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of the following reasons: (a) overexpression in cancer cells
versus noncancerous cells, (b) apical expression in cancer
cells and basolateral expression in normal epithelial cells [8],
and (c) not shed into the circulation [9]. For these reasons Ep-
CAM has gained interest as a potential therapeutic target and
an attractive candidate tumor-associated antigen to serve as a
target for antibody-based immunotherapy [10,11]. There is
evidence  that  Ep-CAM  expression  levels  correlate  with
proliferative  activity  and  contribute  to  neoplastic
transformation [12,13]. These data suggest that Ep-CAM is a
potential target for molecular intervention and that it requires
further investigation.
To define the mechanisms associated with Ep-CAM gene
silencing,  we  investigated  the  effect  of  Ep-CAM  siRNA
treatment on the whole genome expression by microarray
technology.
METHODS
Cell  lines  and  cell  culture:  Y79  was  obtained  from  the
American Type Culture Collection (Manassas, VA). Media
and fetal bovine serum (FBS) were purchased from Gibco-
BRL (Rockville, MD). Y79 was cultured in Rosewell Park
Memorial Institute (RPMI; Gibco-BRL) 1640 supplemented
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828with  10%  heat-inactivated  fetal  calf  serum,  0.1%
ciprofloxacin, 2 mM L-glutamine, 1 mM sodium pyruvate,
and 4.5% dextrose and grown in suspension at 37 °C in a 5%
CO2-humidified  incubator.  The  study  adhered  to  the
Declaration  of  Helsinki.  This  study  was  conducted  at  the
Medical  Research  Foundation  and  Vision  Research
Foundation, Sankara Nethralaya, India, and was approved by
the Vision Research Foundation ethics boards.
Re-expression  of  epithelial  cell  adhesion  molecule  by  5′-
azacytidine: Approximately 1×105 Y79 cells were incubated
in culture medium with and without 5′-azacytidine (AZC) at
a final concentration of 5 µM, with medium changes every
day for 5 days. After day 5, the Y79 cells were withdrawn
from AZC exposure and subsequently passaged for 30 days
in complete medium. Cells were harvested on days 5, 8, 10,
15, and 20 for extraction of total RNA and were tested for Ep-
CAM gene expression, using real-time PCR. Also, 1x105 cells
were harvested on days 5, 8, 10, and 15 and analyzed for Ep-
CAM protein expression, using fluorescence-activated cell
sorting.
RNA interference: Gene silencing of Ep-CAM expression was
performed  essentially  as  described  previously  using
sequence-specific siRNA and transfection reagents [14]. For
each well of cells, 200 nm of siRNA and 12 µl of Hi-perfect
transfection reagent was mixed with 88 µl of serum free RPMI
medium  in  a  vial  and  incubated  for  5–10  min  at  room
temperature  (RT)  to  allow  the  transfection  complex
formation. Then the complex was added drop-wise to the
wells containing Y79 cells and the plate was gently swirled to
ensure the uniform distribution of the transfection complex.
The plates were incubated further for 6 h in a CO2 incubator
at 37 °C. After 4 h of incubation, 400 µl of complete RPMI
medium was added to the wells and incubated further for 24–
72 h. Briefly, 1x105 cells were plated in each well of six-well
plates and allowed to grow for 24–36 h (until they were 40%–
60% confluent). siRNA was then transfected into cells at a
concentration of 200 nM using Hi-Perfect transfection reagent
(Qiagen, Santa Clara, CA) and serum-free medium. After 4 h
of incubation, serum-rich medium was added. Human Ep-
CAM  siRNA  (Hs_TACSTD1_10;  catalog  number
SI04343416; Forward strand: GGA ACU CAA UGC AUA
ACU Att and the reverse strand: UAG UUA UGC AUU GAG
UUC Cct) and scrambled siRNA (catalog number 1022563)
were used in this study.
Epithelial cell adhesion molecule relative RNA quantification
by  real-time  quantitative  reverse  transcriptase  PCR:  To
quantify RNA expression of Ep-CAM in untreated or AZC-
treated Y79 cell lines and untreated or siRNA-treated Y79
cells, RNA was extracted by the guanidine isothiocyanate and
chloroform method (TRI Reagent; Sigma-Aldrich, Bangalore,
India). Cells were harvested from cultures and collected in
RNase  free  vials.  To  the  pellet,  one  ml  of  trizol  reagent
(Sigma-Aldrich)  was  added  and  vortexed  for  2  min  and
incubated at room temperature for 5 min. Later, 0.5 ml of
chloroform was added to the solution and shook well for 15 s
and centrifuged. The aqueous layer that contains RNA was
transferred to new vials and 0.5 ml of isopropanol was added
and  incubated  at  room  temperature  for  10  min.  After
centrifugation, supernatant was discarded and 0.5 ml of 75%
ethanol  was  added  and  mixed  well,  centrifuged  and
supernatant was discarded. Pellet was air dried at RT for 2 min
and  reconstituted  in  25  µl  of  RNase  free  water.  All  the
centrifugations in RNA extraction was performed at 15,000×
g for 10 min at 4 °C. All RNA samples were treated with
DNase  (Turbo;  Ambion,  Genetix  Biotech  Asia  Pvt.  Ltd.,
Chennai, India). For all samples, 1 μg of total RNA was used
to synthesize first-strand cDNA with reverse transcriptase
(SuperScript  II;  Invitrogen,  Joyvel,  Chennai,  India)  and
random primers. The cDNA synthesis was performed at 37 °C
for 60 min after heat inactivation at 95 °C for 10 min. Gene
expression assays for Ep-CAM (Hs00158980_m1) and two
endogenous  controls,  Glyceraldehyde-3-phosphate
dehydrogenase  (GAPDH;  Hs99999905_ml)  and  HPRT
(Hs99999909_m1), were obtained from Applied Biosystems
(LabIndia, Chennai, India). The primer sequences used for Q-
RT–PCR  are  as  follows:  Homo  sapiens  proliferating  cell
nuclear antigen (PCNA): forward primer (FP) 5′- CAG GGC
TCC ATC CTC AAG AA-3′, reverse primer (RP) 5′-TCT
TCA TTG CCG GCG CAT T-3′; FOS: FP 5′-CAG CGA GCA
ACT GAG AAG CC-3′, RP 5′-CGC TGT GAA GCA GAG
CTG G-3′; JUN: FP 5′-CAA AGT TTG GAT TGC ATC AAG
TG-3′, RP 5′-TAA CAT TAT AAA TGG TCA CAG CAC
ATG-3′;  DRAM:  FP  5′-ATG  GTC  ATC  TCT  GCC  GTT
TC-3′,  RP  5′-AAA  GGC  CAC  TGT  CCA  TTC  AC-3′;
CCND3: FP 5′-TGG ATG CTG GAG GTA TGT G-3′, RP 5′-
CGT GGT CGG TGT AGA TGC-3′. Quantification of gene
expression was performed in triplicate in a 20 μl volume in
96-well plates on a real-time PCR system (Prism 7300; ABI,
Lab  India  Instruments,  Gurgaon,  India).  Each  reaction
included 1× primer probe mix (TaqMan; ABI), 1× universal
PCR master mix (TaqMan; ABI), and 100 ng of cDNA. The
PCR was performed as follows: 2 min at 50 °C, 10 min at
95 °C, and 40 cycles of 15 s at 95 °C, plus 1 min at 60 °C.
Commercial  software  (SDS  ver.  1.3;  ABI)  was  used  to
calculate ΔΔCt [15] relative expression values for Ep-CAM
normalized to the GAPDH endogenous control.
Immunocytochemistry: Untreated or siRNA-treated Y79 cells
and untreated or AZC-Y79 cells were harvested, washed, and
then  fixed  in  4%  paraformaldehyde  and  processed  for
immunofluorescence, using anti-Ep-CAM mouse monoclonal
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) as the
primary antibody at a dilution of 1:100 and incubating for 12
h  at  4  °C.  Fluorescein  isothiocynanate  (FITC)-labeled
antimouse  antibody  was  used  as  the  secondary  antibody.
Incubation with the secondary antibody was for 30 min at
37 °C. Immunofluorescence staining was detected using an
Axio Observer fluorescent microscope (Carl Zeiss, Berlin,
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829Germany). Due to the lack of purified Ep-CAM protein, we
could not use an adsorbed control reaction for the negative
control. Instead, we used isotypic antibodies (normal mouse
serum) as negative controls, both for untreated and AZC-
treated  Y79  cells,  in  the  immunohistochemistry.  For
immunohistochemistry,  Novolink  Polymer  kit  (Leica
Microsystems Inc., Bannockburn, IL) was used after primary
antibody  incubation  for  developing  the  reaction,  and
hematoxylin was used for counterstaining. Immunostaining
was assessed based on intensity and was graded as 1+ (low),
2+ (moderate), and 3+ (strong).
Flow cytometric analysis: Y79 cells were harvested, washed,
and the cell number determined. Approximately 3x105 cells/
ml were resuspended in ice-cold phosphate buffered saline
(PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM sodium phosphate
dibasic, 2 mM potassium phosphate monobasic and a pH of
7.4), 10% fetal calf serum, and 1% sodium azide. Mouse
monoclonal primary antibody against Ep-CAM with a final
dilution of 1:40 (C-10; Santa Cruz Biotechnology) was used
and incubated for 2 h at 4 °C. After incubation, cells were
washed three times (at 400× g for 5 min each) with ice-cold
PBS. FITC-conjugated antimouse secondary antibody with a
final dilution of 1:1,000 was used and incubated for 1 h at 4 °C
in the dark. After incubation, cells were washed three times
(centrifugation at 400× g for 5 min each) with ice-cold PBS.
Cells were analyzed on a FACSCalibur flow cytometer (BD
Biosciences, San Jose, CA), using the CellQuest software
program (BD Biosciences). The fluorescence of FITC-stained
cells was excited with an argon laser at 488 nm, and the
emissions were detected at 530 nm.
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide
(MTT) test for 5′-azacytidine cytotoxicity and EpCAM siRNA
effect: Cultures were set up in triplicate and treated or not with
5 μM AZC for 24, 48, 72, 96, and 120 h. After 5 days of AZC
treatment, the cells were washed with PBS and incubated with
complete  medium  for  72  h.  Then,  siRNA  (Qiagen,  Santa
Clara, CA) was added to the plates, and the cells were allowed
to grow for 24, 48, or 72 h. At each time point, cells were
checked  visually  for  growth  and  proliferation.  3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide
(MTT; Sigma, St Louis, MO) was then added to the wells, and
the cells were incubated at 37 °C for 4 h. MTT solubilization
solution (10% Triton X-100 in acidic isopropanol, 0.1 N HCl)
was  then  added,  and  the  cells  were  incubated  overnight.
Colorimetric  measurements  were  made  using  a
spectrophotometer (Beckman Coulter India Private Ltd, New
Delhi, India) at 562 nm, and the background was subtracted
at 650 nm.
Western  blot  analysis:  Cells  were  lysed  in
radioimmunoprecipitation assay lysis buffer for 15 min on ice.
An aliquot (100 µg) of lysate was electrophoresed by 10%
sodium dodecyl sulfate-polyacrylamide gel and blotted onto
a nitrocellulose membrane. Membranes were blocked in 5%
fat-free milk and then incubated separately with 1:500 diluted
mouse monoclonal primary antibody against Ep-CAM (C-10)
overnight  at  4  °C.  β-actin  was  used  as  a  loading  control
(AC-15,  dilution:  1:4,000;  Sigma).  After  washing,
membranes  were  incubated  with  horseradish  peroxidase-
conjugated  antimouse  gamma  immunoglobulin  (IgG)
antibody (diluted to 1:2,000; Santa Cruz Biotechnology) for
1 h at room temperature. The bands were visualized using an
enhanced  chemiluminescence  kit  (Amersham,  Pittsburgh,
PA). Each experiment was performed in triplicate.
Oligonucleotide arrays: Total RNA used for the microarray
analysis  was  isolated  from  cultured  cells  using  TRIZOL
reagent (Invitrogen, Carlsbad, CA) and treated with TURBO
DNase (Ambion, Genetix Biotech Asia Pvt. Ltd., New Delhi,
India) to remove the DNA. The RNA samples (10 μg each) in
a 50-μl reaction were treated with 1 μl of TURBO DNase (2
U) in 1× TURBO DNase buffer at 37 °C for 30 min. After
incubation,  the  RNA  sample  was  extracted  with  phenol/
chloroform to inactivate TURBO DNase. Agilent's (Agilent
Technologies Genotypic, Bangalore, India) Low RNA Input
Linear  Amplification  Kit  PLUS  was  used  to  generate
fluorescent complementary RNA (cRNA). This method uses
T7 RNA polymerase, which simultaneously amplifies target
material  and  incorporates  cyanine  3-labeled  cytidine  tri-
phosphate (CTP). Qiagen’s RNeasy mini spin columns were
used for purification of the amplified cRNA samples, and the
samples were then hybridized to the Human Whole Genome
44K Oligo Microarray for 17 h at 65 °C, as recommended by
the manufacturer (Agilent Technologies). Data analysis was
done  using  Genespring  GX  version  10  (Agilent
Technologies).  Agilent  Feature  Extraction  software
(G25677AA; Agilent Technologies) was used to analyze the
microarray data.
Statistical  analysis:  The  statistical  analysis  included  the
independent t test. Statistical analysis was performed using
SPSS version 12.0 software (Chicago, IL). P values less than
0.05 were considered significant.
RESULTS
Treatment of Y79 cells with 5′-azacytidine promoted an arrest
of cell growth: Y79 cells were exposed to 5 μM AZC for 24,
48,  72,  96,  and  120  h.  We  first  examined  whether  AZC
treatment affected the kinetics of cell growth by evaluating
cell viability using the MTT assay. Cell viability kinetics were
compared to those of control cells cultured in the absence of
AZC.  The  data  of  the  MTT  assay  are  indicative  of  both
viability and cell proliferation. Treatment with AZC greatly
modified  these  data;  around  80%  of  the  number  of
metabolically active cells were observed on day 5 (Figure 1).
This result is consistent with cell cycle arrest in Y79 cells.
Decreased expression of epithelial cell adhesion molecule in
Y79 and its re-expression by 5′-azacytidine treatment: We
previously have observed increased mRNA expression of Ep-
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830CAM in RB primary tumors [6] compared to non-neoplastic
retina (data not shown). In contrast to increased Ep-CAM
expression in primary RB tumors, Y79 showed very faint to
absent  Ep-CAM  protein  expression  by
immunohistochemistry  and  real-time  quantitative  reverse
transcriptase  PCR  (Q-RT–PCR).  Based  on  earlier  studies
[16–19] and the presence of CpG island in the promoter region
of Ep-CAM, we subjected the cell line to a demethylating
agent to find out whether low expression of Ep-CAM is due
to  promoter  methylation.  In  an  attempt  to  re-express  Ep-
CAM, we exposed Y79 to AZC, as described in the methods.
The flow cytometry analysis showed 47.73%, 44.2%, 42.96%,
and 18.27% of Y79 cells positive for Ep-CAM on days 5, 8,
10, and 15 of AZC treatment, respectively (Figure 2A). On
day 5, Y79 cells demonstrated strong membrane positivity for
Ep-CAM by immunohistochemistry (Figure 2G). After day 5,
Y79  cells  were  withdrawn  from  AZC  exposure  and
subsequently passaged in the complete medium up to 30 days,
and Ep-CAM mRNA expression was retained up to 21 days
as follows: 210 fold, 132 fold, 56 fold, and 20-fold on days 8,
10, 15, and 20, respectively (Figure 2J). Thus, AZC treatment
restored adequate Ep-CAM expression, which was sufficient
to perform siRNA experiments in Y79 cells.
EpCAM siRNA treatment decreases proliferation of Y79 cell
line: To determine whether Ep-CAM is a potential target for
RB gene therapy, the Y79 cell line was treated with Ep-
CAM-specific siRNA as well as with scrambled siRNA. The
scrambled siRNA served as a control for nonspecific effects
of  siRNA  treatment  on  cell  growth.  Ep-CAM  protein
expression, mRNA levels, and cell viability were determined
at 24, 48, and 72 h using immunofluorescence (Figure 3A-E),
real-time RT–PCR (Figure 4), and MTT assay (Figure 5),
respectively. The data show that Ep-CAM siRNA treatment
results in 12–13 fold decrease in Ep-CAM gene expression in
the Y79 cell line compared with untreated and scrambled
siRNA-treated Y79 cells at 48 h. Scrambled siRNA treatment
had no effect on Ep-CAM mRNA levels, thus supporting the
specificity of the Ep-CAM siRNA. Similarly, western blot
analysis showed marked decrease in Ep-CAM expression (3.5
fold downregulated when compared to untreated) at 48 h of
Ep-CAM siRNA treatment, whereas no change was shown
when treated with scrambled siRNA (Figure 3F). The Ep-
CAM  siRNA  treatment  effect  was  maximal  at  48  h  and
attenuated by 72 h (consistent with the known transient effects
of siRNA in mammalian cells). Ep-CAM siRNA treatment
resulted in a significant decrease in cell proliferation by more
than 50% at all time points.
cDNA microarray: Ep-CAM expression was decreased by 12–
13 fold, which was minimum at 48 h after siRNA treatment;
hence at this time point cells were harvested for microarray
analysis. The genome-wide expression profile of Ep-CAM
siRNA-treated  AZC-Y79  cells  against  siRNA-untreated
AZC-Y79 was analyzed to investigate the molecules involved
in Ep-CAM signaling. In Y79 cells, anti-Ep-CAM siRNA
treatment modulated the expression of 670 gene transcripts
(probe sets), 465 (69.4%) of which were increased and 205
(30.5%) were decreased. Only genes with p≤0.05 and log ratio
of  at  least  2.0  for  upregulation  and  log  ratio  of  0.5  for
downregulation,  keeping  a  median  log  ratio  of  1  in  both
biologic replicates, were considered for expression analysis.
The important upregulated and downregulated genes post Ep-
CAM knockdown (Figure 6) are provided in Table 1 and Table
2, respectively. The data discussed in this publication have
been deposited in NCBI's Gene Expression Omnibus [20] and
are  accessible  through  GEO  Series  accession  number
GSE16991.
Figure  1.  The  effect  of  azacytidine
(AZC) treatment on retinoblastoma Y79
cell survival for 5 days was determined
by  3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium  bromide  (MTT
assay).The bar diagram shows that 80%
percent of Y79 cells were viable on 5th
day  of  AZC  treatment  at  5  µM
concentration. Error bar represents the
standard deviation of triplicate values.
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831Figure 2. The retinoblastoma Y79 cell line was treated with 5 µM Azacytidine (AZC) and the epithelial cell adhesion molecule (Ep-CAM)
expression was studied by flow cytometry analysis (FC), Immunohistochemistry (IHC) and real time quantitative reverse transcriptase
polymerase chain reaction (Q-RT–PCR). A-E: M1 represents the EpCAM percentage positivity in the FC graphs (solid line). FC analysis
demonstrated 47.73%, 44.2%, 42.96%, and 18.27% of Y79 cells positive for Ep-CAM on days 5, 8, 10, and 15 of AZC treatment, respectively.
F-I: Immunohistchemistry pictures stained with Di-amino benzidine (DAB) and was counter stained with hematoxylin. All the pictures were
captured at 20 times magnification. EpCAM was not stained in Y79 cells not treated with AZC (F); Strong membrane positive expression of
Ep-CAM was seen in Y79 cells treated AZC on 5th day (G); Strong membrane positivity of Ep-CAM in the retinoblastoma primary tumor
represented as positive control (H); Y79 cells were stained negative when isotypic antibodies were used as the negative control (I). Q-RT–
PCR shows the mRNA expression of Ep-CAM in Y79 cells after 5 days of AZC treatment (J). After day 5, Y79 cells were withdrawn from
AZC exposure and subsequently passaged in the complete medium up to 30 days, and Ep-CAM mRNA expression was retained up to 21 days
as follows: 210-fold, 132-fold, 56-fold, and 20-fold on days 8, 10, 15, and 20 days, respectively. The error bars represents the standard deviation
of triplicate values (J).
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832Upregulated  genes  post  epithelial  cell  adhesion  molecule
knockdown:  In  cells  with  inhibited  Ep-CAM  expression,
upregulated categories represented gene products that were
involved in apoptosis, such as lactalbumin, alpha (LALBA),
retinoic acid receptor, gamma (RARG), ataxin 3 (ATXN3),
mitogen-activated protein kinase 13 (MAPK13), tubulin, beta
2A  (TUBB2A),  activating  transcription  factor  3  (ATF3),
insulin-like growth factor binding protein 1 (IGFBP1), Homo
Figure 3. Effect of small interfering RNA on the expression of epithelial cell adhesion molecule in retinoblastoma Y79 cells in vitro.
Immunofluorescence picture shows the negative staining without Epithelial cell adhesion molecule (Ep-CAM) antibody in Y79 cells
representing as negative control (A); Immunofluorescence shows strong positivity (3+; white arrows) for Ep-CAM on day 8 post azacytidine
treatment (B); After 24 h of short interfering (si)RNA treatment, Y79 cells showed moderate staining (2+; arrows) of Ep-CAM (C). After 48
h of siRNA treatment, Y79 cells showed dull staining (1+; arrows) of Ep-CAM (D). After 72 h of siRNA treatment, Y79 cells gain Ep-CAM
expression (low to moderate intensity). E: western blot analysis demonstrates strong expression of Ep-CAM in Y79 cells that are si-RNA
untreated (lane 1), strong expression in Y79 cells treated with scrambled siRNA (lane 2) and markedly reduced Ep-CAM expression in Y79
cells treated with Ep-CAM-siRNA (F; lane 3).
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833sapiens damage-regulated autophagy modulator (DRAM), and
cytochrome c, somatic (CYCS); anti-angiogenic genes, such
as  lectin,  galactoside-binding,  soluble,  3  (LGALS3),  and
vasohibin 1 (VASH1); cell cycle and differentiation genes,
such as LGALS3, 5-hydroxytryptamine (serotonin) receptor
5A (HTR5A), INS, tachykinin 3 [neuromedin K, neurokinin
beta] (TAC3), and ATF3; anti-proliferation genes, such as
spectrin repeat containing, nuclear envelope 2 (SYNE2), BTB
and  CNC  homology  1,  basic  leucine  zipper  transcription
factor 2 (BACH2), tripartite motif-containing 8 (TRIM8), Rac
GTPase activating protein 1 (RACGAP1), and MEG3; and
tumor suppressor gene tropomyosin 1 alpha (TPM1).
Downregulated genes post epithelial cell adhesion molecule
silencing:  Downregulated  categories  represented  gene
products that were involved in cell cycle and cell division
genes, such as MYC-associated zinc finger protein [purine-
Figure  4.  Epithelial  cell  adhesion
molecule-  short  interfering  RNA
treatment  decreases  the  mRNA
expression  of  epithelial  cell  adhesion
molecule  in  Y79  cells.  The  mRNA
levels  of  Epithelial  cell  adhesion
molecule  (Ep-CAM)  in  Y79  cells
treated with Ep-CAM- short interfering
(si)RNA  was  decreased  by  11-fold
(p<0.001),  12-fold  (p<0.001)  and  5.5
fold  (p<0.01)  at  24,  48,  and  72  h
respectively when compared with Ep-
CAM mRNA levels in Y79 cells treated
with scrambled (SCR) siRNA (dotted
bars). The mRNA levels of Ep-CAM in
Y79 cells treated with Ep-CAM-siRNA
was decreased by 11-fold (p<0.001), 12-
fold (p<0.001) and fivefold (p<0.01) at
24,  48,  and  72  h,  respectively,  when
compared with Ep-CAM mRNA levels
in  control  (CTRL)  Y79  cells  (solid
bars).  The  error  bars  represents  the
standard deviation of triplicate values
and  the  statistical  analysis  was
performed using independent t-test.
Figure  5.  epithelial  cell  adhesion
molecule  short  interfering  RNA
treatment  decreases  the  cell
proliferation of Y79 cells. The Y79 cells
were  treated  with  epithelial  cell
adhesion  molecule  epithelial  cell
adhesion  molecule  epithelial  cell
adhesion  molecule  (Ep-CAM)  short
interfering  (si)RNA  and  the  cell
proliferation was assessed at 24, 48, and
72  h  using  3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium  bromide
(MTT) assay. The viability of Y79 cells
was  54%  (p<0.01),  55%  p<0.01)  and
60% (p<0.01) at 24, 48, and 72 h of
siRNA  treatment  respectively  when
compared  to  Y79  cells  that  were  not
treated  with  siRNA.  The  error  bars
represents  the  standard  deviation  of
triplicate  values  and  the  statistical
analysis  was  performed  using
independent t-test.
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834binding  transcription  factor]  (MAZ),  tubulin,  epsilon  1
(TUBE1), MAD1, sprouty-related, EVH1 domain containing
1  (SPRED1),  U2  small  nuclear  RNA  auxiliary  factor  1
(U2AF1), CNDP, and stress induced growth inhibitor family
member 2 (SGIN2); cell migration genes, such as MMP2, cell
division cycle 42 [GTP binding protein, 25 kDa] (cdc42), and
MADS box transcription enhancer factor 2, polypeptide A
[myocyte  enhancer  factor  2A]  (MEF2A);  anti-apoptotic
genes, such as DnaJ (Hsp40) homolog, subfamily A, member
3  (DNAJA3),  ornithine  decarboxylase  1  (ODC1),  gelsolin
[amyloidosis, Finnish type] (GSN), BCL2-like 1 (BCL21), and
high-mobility  groupbox  1  (HMGB1);  proliferation  genes,
such as FGF9, Homo sapiens v-fos FBJ murine osteosarcoma
viral oncogene homolog (FOS), Homo sapiens jun oncogene
(JUN),  PCNA,  Homo  sapiens  E2F  transcription  factor  3
(E2F3), malignant T cell amplified sequence 1 (MCTS1),
hairy and enhancer of split 1, [Drosophila] (HES1), cyclin D3
(CCND3), growth arrest and DNA-damage-inducible, alpha
(GADD45A), embryonic lethal, abnormal vision, Drosophila-
like 1 [Hu antigen R] (ELAVL1), nuclear receptor coactivator
1  (NCOA1),  enolase  1,  [alpha]  (ENO1),  and  insulin-like
growth factor 1 [somatomedin C] (IGF1); and oncogenes,
such as FOS, member of RAS oncogene family (RAP2C),
member  RAS  oncogene  family  (RAB8A),  JUN,  sarcospan
[Kras oncogene-associated gene] (SSPN), RAB1B, RAB15,
and  v-myc  myelocytomatosis  viral  related  oncogene,
neuroblastoma derived [avian] (MCYN).
Deregulated pathways post epithelial cell adhesion molecule
silencing: Upon Ep-CAM inhibition, MAP kinase pathway
was deregulated in Y79 cells. The genes involved in MAP
kinase pathway were FOS, JUN, FGF9, and GADD45A. On
the  other  hand,  P53  pathway  molecules  were  upregulated
upon  Ep-CAM  inhibition.  The  molecules  involved  in  P53
pathway were RRM2, CYCS, and DRAM.
Functional grouping of differentially expressed genes: All the
distinct gene identifications were examined for their known
biologic function according to gene ontology convention and
grouped in the respective functional category. The proportion
of each functional category in the total number of selected
identified genes (taken as 100%) is shown in Figure 7. Among
the  upregulated  genes,  (Figure  7A)  the  majority  of  genes
belong to the apoptosis functional category (48%). Hence, it
is  interesting  to  speculate  that  Ep-CAM  inhibition  may
promote apoptosis in Y79 cells. Other genes identified belong
to  proliferation,  anti-proliferation,  angiogenesis,  anti-
angiogenesis,  anti-apoptotic,  and  tumor  suppressor  genes.
Among the downregulated genes, (Figure 7B) one-third of the
total genes belong to the proliferation functional category
(33%)  and  cell  cycle  and  differentiation  (33%).  Other
downregulated  genes  belong  to  cellular  invasion,  anti-
apoptosis, oncogenes, and angiogenic genes.
Real-time quantitative reverse transcriptase-PCR to confirm
microarray data: Five genes (PCNA, CCND3, FOS, JUN, and
DRAM) from microarray data have been confirmed by real-
time  Q-RT–PCR.  The  results  are  consistent  with  the
microarray data. The gene expression of all five genes studied
was higher when measured using Q-RT–PCR as compared to
microarray analysis, reflecting the better dynamic range of Q-
RT–PCR.  The  relative  mRNA  expression  of  DRAM  was
significantly increased, and the relative mRNA expression of
PCNA,  CCND3,  FOS,  and  JUN  were  significantly
downregulated  in  siRNA-treated  Y79  cells  compared  to
untreated Y79 cells (Figure 8).
DISCUSSION
To investigate the functional relevance of Ep-CAM in RB, we
proposed  to  transiently  silence  Ep-CAM  expression  using
siRNA  and  study  its  effect  on  whole  gene  expression
profiling. We chose the Y79 cell line for in vitro studies for
two reasons. One reason is that Y79 cells form tumors in the
murine model that closely resemble the naturally occurring
tumor in anatomic sites without disrupting the choroid or
sclera or involving the anterior chamber [21]. The second
reason is that as RB tumors from Indian RB patients are
Figure 6. Epithelial cell adhesion molecule short interfering RNA treatment leads to changes in gene expression profile in Y79 cells. The heat
map represents the expression profile of 100 genes differentially modified in response to knockdown of epithelial cell adhesion molecule (Ep-
CAM) in Y79 cells compared to untreated cells. The horizontal lines represent the relative fold change in the expression of individual genes
modified by the Ep-CAM-short interfering (si)RNA. Red and green indicate increased and decreased expression, respectively, relative to
nonsilencing control siRNA.
Molecular Vision 2010; 16:828-842 <http://www.molvis.org/molvis/v16/a93> © 2010 Molecular Vision
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838advanced tumors, presenting with choroidal and optic nerve
invasion [22], the Y79 cell line is appropriate for in vitro
studies and the data can be translated to the actual tumor state.
Our study shows that both mRNA and protein levels of
Ep-CAM  are  very  low  to  absent  in  Y79  cells.  There  is
substantial evidence that DNA methylation plays an important
role in silencing specific genes during development and cell
differentiation [23,24]. Earlier studies have shown that Ep-
CAM is regulated by the most common epigenetic mechanism
—hypermethylation  in  oral  squamous  cell  carcinoma  and
breast carcinomas [16–19]. Epigenetic silencing of a gene can
be  reversed  by  drugs,  such  as  AZC,  which  acts  through
incorporation  of  the  modified  nucleotide  in  the  place  of
cytosine  into  the  newly  synthesized  strand  during  DNA
replication.  The  modified  nucleotides  form  a  covalent
complex with the active sites of the DNA methyltransferase,
depleting methyltransferase activity, resulting in generalized
demethylation  [25].  In  this  context,  we  restored  Ep-CAM
expression  in  Y79  cells  by  subjecting  the  cells  to
demethylation (AZC treatment) in vitro for 5 days. However,
these drugs have effects other than inducing demethylation.
The amount of methylation and the response obviously can
vary for the same gene from one cell line to another and
between  different  genes  in  the  same  cell  line.  One
disadvantage of a drug-based reactivation approach is that,
unlike CpG island array screening, use is essentially restricted
to cell cultures and is not amenable to examination of primary
tumors.
In the present study, AZC treatment restored adequate
Ep-CAM expression, which was sufficient to perform siRNA
experiments in Y79 cells. Silencing of the Ep-CAM gene
significantly decreased the proliferative capacity of RB Y79
cells. Expression microarray analysis of Ep-CAM silencing
revealed several genes related to cell proliferation, apoptosis,
anti-apoptosis, cell division and differentiation, angiogenesis,
anti-angiogenesis, and oncogenes.
Cells expressing Ep-CAM proliferate more rapidly, grow
in an anchorage-independent manner, and have a reduced
requirement for growth factors. Consistent with the growth-
promoting role of Ep-CAM, knockdown of endogenous Ep-
CAM in tumor cells decreases cell proliferation and migration
[7,26]. The role of Ep-CAM in proliferation and its association
Figure  7.  Functional  grouping  of
upregulated  genes.  (A)  and
downregulated genes (B) in Y79 cells
treated  with  epithelial  cell  adhesion
molecule short interfering (si)RNA. All
the  distinct  gene  identifications  were
examined  for  their  known  biologic
function  according  to  gene  ontology
convention  and  grouped  in  the
respective  functional  category.  The
proportion of each functional category
in the total number of selected identified
genes (taken as 100%) is shown.
Figure  8.  The  mRNA  expression  of
selected genes from microarray data was
confirmed using real time quantitative
reverse  transcriptase  PCR  (Q-RT–
PCR).  The  black  bars  represent  the
mRNA levels quantified by Q-RT–PCR
and  the  white  bars  represent  the  fold
expression  of  genes  studied  by
microarray. The Q-RT–PCR results are
consistent with microarray results. The
error  bars  represent  the  standard
deviation  of  triplicate  values.
Abbreviations:  PCNA  represents
proliferating  cell  nuclear  antigen,
CCDN3  represents  cyclin  D3,  FOS
represents  v-fos  FBJ  murine
osteosarcoma viral oncogene homolog,
JUN  represents  jun  oncogene,  and
DRAM  represents  damage-regulated
autophagy modulator.
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839with cancer is poorly explained by proposed cell adhesion
functions. Recently, Maetzel et al. [27] showed that regulated
intramembrane proteolysis activates Ep-CAM as a mitogenic
signal transducer in vitro and in vivo. The cleaved intracellular
domain  Ep-CAM  intracellular  domain  (EpICD)  associates
with four and a half LIM domain (FHL2), β-catenin, and
lymphoid enhancer binding factor 1 (Lef-1) to form a nuclear
complex that contacts DNA at Lef-1 consensus sites, induces
gene transcription, and is oncogenic in immunodeficient mice.
Hence,  this  mechanism  of  nuclear  signaling  of  Ep-CAM
explains how it functions in cell proliferation.
Our study showed significant downregulation of PCNA
post-Ep-CAM silencing. A high PCNA index has been noted
in RB in a recent study by Dimaras et al. [28]. In gastric cancer,
the PCNA index of gastric cancer tissues with high Ep-CAM
expression was higher than gastric cancer tissues with low Ep-
CAM expression, indicating that Ep-CAM might be associated
with the proliferative activity of cancer cells [29]. We also
showed that FOS and JUN, which are involved in cellular
proliferation, were downregulated post-Ep-CAM silencing.
Genes related to apoptosis, such as damage-regulated
autophagy  modulator  DRAM,  a  critical  effector  of  p53-
induced autophagy [30], and cytochrome c CYCS, a central
molecule  in  apoptotic  signaling  [31],  were  significantly
upregulated.  Recently,  a  study  on  mammary  tissues  in
transgenic mice showed that Ep-CAM overexpression could
induce  Ki-67  upregulation  and  reduce  apoptosis  of  cells,
accompanied by upregulation of bcl-2 expression, which was
the  first  report  about  the  relation  between  Ep-CAM  and
apoptosis  [32].  Our  observations  indicate  that  Ep-CAM
inhibition  on  cellular  proliferation  is  by  cell  cycle  arrest
accompanied  by  apoptosis.  However,  further  functional
studies need to be conducted to prove these effects in RB.
These  changes  are  coupled  with  downregulation  of
important cell cycle-related transcription factors, E2F3 and
CCND3. E2Fs are transcription factors best known for their
involvement  in  the  timely  regulation  of  gene  expression
required for cell cycle progression. E2F3 overexpression has
been previously demonstrated in RB tumors by Gallie et al.
[33]. Cyclins are periodic regulatory proteins governing cell
cycle transit from G1 phase into S phase. Overexpression of
cyclins could lead to abnormal cellular proliferation, which
underlies the process of tumorigenesis [34].
Interestingly, our study showed the downregulation of
MYCN  post-Ep-CAM  silencing.  MYCN  is  a  well  studied
oncogene known to be amplified in neuroblastoma [35] and
in  a  subset  of  RB  tumors  [36,37].  Previously  it  was
demonstrated that Ep-CAM has a direct impact on the cell
cycle and proliferation and the ability to rapidly upregulate
the  proto-oncogene  c-myc  and  cyclin  A/E  [21].  However,
further studies are needed to establish the MYCN relation with
Ep-CAM signaling in RB.
In  addition  to  proliferation  and  apoptotic  genes,  we
showed that genes related to tumor invasion, metastasis, and
angiogenesis,  such  as  MMPs  and  cdc42  are  significantly
downregulated  post  Ep-CAM  silencing.  Previously  we
demonstrated high MMP [38] and cdc42 [39] expression in
RB primary tumors. The downregulation of MMPs in the
present study supports the hypothesis that Ep-CAM inhibition
could reduce tumor cell invasion, as demonstrated in an earlier
study [7]. Ep-CAM inhibition led to downregulation of the
MAP kinase pathway in Y79 cells. The genes involved in the
MAP kinase pathway are FOS, JUN, FGF9, and GADD45A.
On the other hand, P53 pathway molecules were upregulated
upon Ep-CAM inhibition. The molecules involved in the P53
pathway are RRM2, CYCS, and DRAM.
In conclusion, we showed for the first time that Ep-CAM
silencing  in  RB  in  vitro  leads  to  a  decrease  in  Y79  cell
proliferation and deregulation of several genes related to cell
survival/proliferation,  DNA  replication/transcription,
apoptosis,  and  angiogenesis.  Targeting  Ep-CAM  for
molecular intervention appears to be an attractive strategy.
First, Ep-CAM is substantially overexpressed in primary RB
tumor  samples  [6].  Furthermore,  because  Ep-CAM
overexpression is associated with proliferation and neoplastic
transformation [40,41], silencing of Ep-CAM gene expression
is likely to dramatically alter the phenotype of cancer cells
without significantly influencing normal or nonproliferating
cells. Future studies targeting Ep-CAM gene expression in
vivo will help to delineate the mechanisms associated with
Ep-CAM  gene  function  in  neoplastic  transformation  and
define the potential for Ep-CAM-based molecular intervention
in RB patients.
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